China Resources Jiangzhong Pharmaceutical Co Ltd
China Resources Jiangzhong Pharmaceutical Co.,Ltd engages in the manufacture of pharmaceutical products in China. The company offers OTC products, including stomach-strengthening and digestion-promoting tablets, lactobacillus tablets, triple live bifidobacterium enteric-coated capsules, compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, fritillaria and loquat capsules, bezoar and snake gallbladder fritillaria liquid, and compound gold melon seed. It also provides health consumer and other products, such as nourishing, tonics, rehabilitation nutrition, gastrointestinal health, and liver health products. In addition, the company offers prescription drugs comprising traditional Chinese medicine products, which includes Shenbao capsules, Paishi granules, Huangba Shengmai drink, Bazhen Yimu capsules; chemical medicine products, such as lumbrokinase enteric-coated capsules, Rabeprazole sodium enteric-coated tablets, chloroprocaine hydrochloride, etc.; and medicinal materials which includes codonopsis pilosula. The company was formerly known as Jiang Zhong Pharmaceutical Co.,Ltd and changed its name to China Resources Jiangzhong Pharmaceutical Co.,Ltd in January 2025. China Resources Jiangzhong Pharmaceutical Co.,Ltd was founded in 1996 and is headquartered in Nanchang, China.
If you'd bought from year…
Same habit, different start year. Each row shows what a constant habit's worth of 600750-SS would be worth today, had you started buying at that point in the asset's history.
| Started | $6/day$6/day coffee | $42/wk$42/week coffee |
|---|---|---|
| Year 1 (1996) — listing | $388,504 8.8× | $551,862 8.6× |
| Year 6 (2001) | $274,963 7.3× | $392,575 7.2× |
| Year 11 (2006) | $119,304 4.0× | $174,549 4.0× |
| Year 16 (2011) | $58,686 2.6× | $86,506 2.6× |
| Year 21 (2016) | $33,908 2.2× | $49,799 2.2× |
| Year 26 (2021) | $13,465 1.7× | $19,901 1.7× |
Repeated investment, no fees, dividends reinvested. $6/day coffee = $180 / month equivalent.
Popular scenarios with 600750
For illustration only — not investment advice. Past performance is not indicative of future results.